drugset / Trial / NCT05433896
Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions
Non-randomizedSequentialOpen-labelOther
Summary
In this open label, single-sequence study, subjects received one dose of XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation at the start of study on Day 1 and Day 6. Omeprazole 40 mg was administered on Day 2, 3, 4, 5 and 6. The study was conducted in two groups.
Timeline
- Start
- 2020-11-01
- Primary completion
- 2020-12-19
- Completion
- 2020-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 90 mg | Oral |
Indications
No indication recorded.